Navigation Links
Passing of Genmab A/S' Annual General Meeting
Date:4/23/2008

COPENHAGEN, April 23 /PRNewswire-FirstCall/ -- Summary: At Genmab A/S' Annual General Meeting held today on April 23, 2008 the Annual Report for 2007 was approved, discharge was given to the Board of Directors and the Management and the year's loss was carried forward. Two members of the Board of Directors were re-elected and PricewaterhouseCoopers was re-elected as auditor of the Company. The proposals from the Board of Directors to change the Articles of Association and authorization to allow the Company to purchase shares in the Company were adopted.

Genmab A/S (OMX: GEN) held its Annual General Meeting, today April 23, 2008 at 3:00 pm at Radisson SAS Scandinavia Hotel, Amager Boulevard 70, 2300 Copenhagen S, Denmark.

At the meeting Chairman of the Board Dr. Michael B. Widmer gave - on behalf of the Board - a report on the Company's activities during the past year. Chief Executive Officer and member of the Board, Lisa N. Drakeman presented plans for the year ahead, and Chief Financial Officer Bo Kruse presented the Annual Report for 2007 endorsed by the auditors. The report was approved and discharge was given to the Board and the Management.

It was decided that the year's loss of DKK 373 million be carried forward by transfer to accumulated deficit, as stated in the Annual Report.

Michael B. Widmer and Karsten Havkrog Pedersen were re-elected to the Board for a further three year period.

PricewaterhouseCoopers, Statsautoriseret Revisionsaktieselskab A/S was reelected as the Company's auditor.

The General Meeting adopted the proposals from the Board to change the Company's Articles of Association, as follows:

- The proposals to remove the current Article 5, Article 6 and Schedule A and to make the consequent amendments to the Articles of Association.

The proposal to amend Article 5 (previously Article 6A) to authorize the Board of Directors to issue additional warrants - without pre-emption rights for
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... the hormonal messengers responsible for most of the biological effects ... type responses. T lymphocytes are a major source of cytokines. ... allow recognition of foreign pathogens. There are two main subsets ... molecules known as CD4 and CD8. T lymphocytes expressing CD4 ...
... Michael Leist Varian , ... E-mail: icpms@varianinc.com , Introduction ... and bioavailability can differ greatly between the various chemical species in ... be misleading. Arsenic is one such example where the various species ...
... Z. Yang, Varian, Inc. , ... Nitrofuran antibiotics are veterinary drugs. The use of ... Australia, Canada, Japan, Singapore, Bangladesh, and the European Union because of ... Trace amounts of nitrofurans contamination has been found ...
Cached Biology Technology:Th1 and Th2 Balance, Regulation, and Involvement in Disease 2Speciation of Arsenic by LC-ICP-MS 2Speciation of Arsenic by LC-ICP-MS 3Speciation of Arsenic by LC-ICP-MS 4Speciation of Arsenic by LC-ICP-MS 5Analysis of Nitrofurans Metabolites by Positive Ion Electrospray LC/MS/MS 2
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ... team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... researchers have discovered Salmonella bacteria that are up ... may help prevent food poisoning outbreaks that continue to plague ... can override vaccines and pose a risk to food safety ... strategies to find the more dangerous bugs were unsuccessful since ...
... CA April 18, 2012 Scientists at The Scripps ... mice from an otherwise lethal overdose of cocaine. The findings ... to reverse the effects of cocaine in case of emergency. ... about 5,000 overdose deaths each year in the United States. ...
... Maastricht, 17 April 2012 The Second European ... Netherlands, brings together high-level researchers, policymakers and practitioners to ... sectors of energy will share their ideas on how ... of environmental and climate impact and also in terms ...
Cached Biology News:UCSB researchers discover particularly dangerous Salmonella 2Scripps Research Institute scientists develop antidote for cocaine overdose 2Scripps Research Institute scientists develop antidote for cocaine overdose 3